Cyclooxygenase (COX)2 inhibitors are candidate agents for chemoprevention in non-invasive bladder cancer, since activation of FGFR1 signaling has been shown to induce EMT in UC by promoting phospholipase C gamma-mediated upregulation of COX2 [11]. Here, FGFR1 is linked to urinary bladder cancer.